The Dow, Nasdaq and S&P 500 are all down today, and there are more losers than winners. Like many of the winners and losers of the previous week, two of the three on today’s list are pharmaceutical companies seeking approval for new drugs. Meanwhile, the other company on the list is a smartphone maker trying to find its place among an increasingly crowded market.
Here are today’s winners and losers:
Shares of Alexza Pharmaceuticals (NASDAQ: ALXA) are up 15.87% to $4.60 based on trading volume of 1.8 million shares. The company announced Monday it filed a new marketing application for Adasuve, its drug to treat acute agitation from schizophrenia or bipolar disorder. The company is also in discussions for approval with the European Union, according to the Associated Press.
Shares of Ventrus Biosciences (NASDAQ: VTUS) are down 56.16% to $5.38 based on trading volume of 2.3 million shares. This drop comes after the company plans to end its efforts to get approval for VEN 309, a drug intending to treat piles. According to news reports, the drug didn’t eliminate bleeding compared to a placebo in a late-stage trial.
Shares of Nokia (NYSE: NOK) are down 8.82% to $2.17 based on trading volume of 15.8 million shares. Nokia has really struggled as of late. The company announced reduced earnings estimates earlier this month and also said it was going to eliminate 10,000 jobs. Meanwhile, rival Samsung is expected to have strong earnings this quarter due to sales of the Galaxy smartphone.